

ATYPICAL PRESENTATION IN LANGERHANS CELL HISTIOCYTOSIS: Hearing Loss, Diabetes Insipidus, & Extensive Cutaneous Lesions with Nail Dystrophy

LANGERHANS HÜCRELİ HİSTİOSİTOZDA ATİPİK PRESENTASYON: İşitme Kaybı, Diabetes İnsipitus & Tırnak Distrofisi ile Beraber Geniş Kutanöz Lezyonlar

Cemil Hocasade¹, Mutlu Doğan¹, Ahu Yorulmaz², Servet Güreşçi³, Deniz Cılız⁴, Elvan Evrim Tuna⁵,
Nurullah Zengin¹

¹Ankara Numune Eğitim ve Araştırma Hastanesi, Medikal Onkoloji Kliniği

²Ankara Numune Eğitim ve Araştırma Hastanesi, Dermatoloji Kliniği

³Ankara Numune Eğitim ve Araştırma Hastanesi, Patoloji Kliniği

⁴Ankara Numune Eğitim ve Araştırma Hastanesi, Radyoloji Kliniği

⁵Ankara Numune Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Kliniği

Dergiye Ulaşma Tarihi: 15.03.2016 Dergiye Kabul Tarihi: 23.03.2016 Doi: 10.5505/aot.2017.70299

ÖZET

Langerhans hücreli histiositoz (LCH) CD-1a boyanması gösteren klonal proliferatif lenfositik bir hastalıktır. Hastalık unifokal veya multifokal tek bir sitemi veya birçok sitemi tutacak şekilde geniş bir klinik seyir gösterebilir. Tutulan alana göre diabetes insipidus, işitme kaybı veya tırnak değişiklikleri oluşabilir. Burada atipik presentasyon gösteren iki vakayı literatür derlemesi ile beraber sunduk.

Anahtar Kelimeler: Langerhans hücreli histiositoz, diabetes insipidus, işitme kaybı, tırnak distrofisi

ABSTRACT

Langerhans cell histiocytosis (LCH) is a clonal proliferative lymphohistiocytic disorder with mainly CD-1a positive staining. It has a wide spectrum of unifocal or multifocal mono or multisystemic disease. Rare symptoms like diabetes insipidus, hearing loss or nail dystrophy might also occur according to the involved sites. In here, two cases of LCH with atypical presentation are reported with review of the literature.

Keywords: Langerhans cell histiocytosis, diabetes insipidus, hearing loss, nail dystrophy

Background

Langerhans cell histiocytosis (LCH) which was known as histiocytosis-X formerly is a rare clonal proliferative lymphohistiocytic disorder accompanying with skeletal (osteolytic bone metastasis) or extraskelatal lesions such as visseral, skin or central nervous system (CNS) involments (1-3). It occurs with an estimated incidence of 4-4,6 per million in childhood and 1-2 per million in adults (4). Aberrant immunmodulation with a predominance of large, mononuclear CD1a-positive dendritic cells infiltration has a key role in pathogenesis. S-100, CD1a & CD207 positivity on immunohistochemical (IHC) staining is a cornerstone in histopathological diagnosis (5,6).

The clinical presentation and severity depend on the involved regions (2-4,7). Billiary cirrhosis, diabetes insipidus (DI) or hearing loss in mastoid infiltration might also occur in rare involvements of liver, CNS or mastoid (8-10). The prognosis and treatment modalities (local / systemic) depend on the sites and extent of the disease. Spontaneous regressions might also occur in those with limited involvement (11).

Langerhans cell histiocytosis in two cases with atypical presentations is discussed in this report with review of the literature.

Case 1

A 24-year old female was admitted to the hospital with disseminated skin lesions and icterus, hyperbilirubinemia with transaminase elevation besides constitutional symptoms such as weight loss, malaise and disseminated pain.

She had non-healing wounds on her face, neck, armpits and groins. She has had skin lesions and dystrophic nail changes for 9 years and intermittent polydipsia for a year on history. Her skin & nail lesions worsened during last year. She was referred to our center after she has progressed with vincristine and prednisone upon an unclassified lymphoproliferative disorder on pathology at another center. She had hypothyroidism with no remarkable family history. On physical examination, she had generalized bilaterally cervical, occipital & axillary lymphadenopathy (LAP) besides hepatomegaly. In addition, she had left abducens nerve palsy on ophthalmological evaluation. Upon dermatologic examination, we observed numerous erythematous-brownish papules with serous to thick hemorrhagic crusts with confluence to form plaques distributed over face, scalp, flexural areas, nipples and areolas (Figure 1a, 1b, 1c); exophytic, vegetative tumours with multilobulated surface on perioral, nasolabial regions and chin (Figure 1a); moist red eroded and ulcerated areas in axillary and inguinal regions (Figure 1b, 1c) and onychia of all finger nails (Figure 1d). Her repeated skin biopsy revealed LCH with epidermal ulceration and subepidermal atypical histiocytoid cell infiltration with giant nuclei and pale cytoplasm. These cells had 'coffee bean-like' nuclei in papillary dermis extending into the epidermis with an admixture of inflammatory cells like eosinophils, neutrophils, lymphocytes and plasma cells in the dermis (figure 2a). Histiocyte markers (S100, CD1a) were positive on IHC staining (figure 2b, 2c). Laboratory tests were suggestive of hyperbilirubinemia (total/direct bilirubin: 7,3/6,2 mg/dL) and elevation of transaminases [aspartate aminotransferase (AST): 221 IU/L, alanine aminotransferase (ALT): 423 IU/L], alkaline phosphatase (ALP): 2873 IU/L, gamma-glutamyl transpeptidase (GGT): 3020 IU/L and lactate dehydrogenase (LDH): 4726 IU/L, respectively. She had hyponatremia (128; N=135-145 mEq/L), with high levels of prolactin (28,79; N=4,23-23, 3 ng/mL) & thyroid-stimulating hormone (7,5; N=0,27-4,2 μ IU/mL). She had no bone marrow involvement. She had heterogeneity and hyperechogenic thickening around portal vein on liver ultrasonography (US) while she had a 38x32x29 mm solid lesion with cystic and necrotic components in the pons extending to

the cerebellary peduncles and indentation to the fourth ventricle on magnetic resonance imaging (MRI) (figure 3a, 3b, 3c). There were disseminated cervical, supraclavicular, axillary and intraabdominal LAPs with a greatest diameter of 40x11 mm close to the left carotid artery on toracoabdominal computerized tomography (CT). She had also disseminated millimetric cystic nodular pulmonary lesions with cystic hepatic involvement which were considered as LCH involvement after other causes were ruled out. She had central hypothyroidism without an additional thyroidal involvement. She had prominent regression in the LAPs, skin & nail lesions after one cycle of Ara-C and steroid. Hypothyroidism & DI were under control with thyroxin & vasopressine. However, radiotherapy (RT; 30 Gy) had to be applied for worsening left hemiparesis after the first cycle. She had radiation recall phenomena (RCP) though RCP is not so common with Ara-C (12). Second cycle of chemotherapy had to be delayed for 10 days after RT. Hyperbilirubinemia (total/direct bilirubin: 30,4/15 mg/dL, & transaminase elevation (AST: 218 IU/L, ALT: 518 IU/L) worsened rapidly in the following days. She was given dose-adjusted Ara-C & steroid with closer follow-up. She had clinical benefit especially in the skin lesions after two cycles, however hyperbilirubinemia persisted almost in less high levels (total/direct bilirubin: 16/8,2 mg/dL). She got worsened in the following weeks and lost-of follow-up after five weeks of best supportive care.

Case 2

A 37-year old male referred to our center with hearing loss. On physical examination, he had a 5x5mm polypoid lesion on external ear canal and a mobile 6,5x5 cm mass on his right scapula. He had a mass on his right mastoid on the posterior wall of the external ear canal involving petrous component and semicircular canals, extending to the sigmoid sinus with loss of right mastoid aeration on magnetic resonance imaging (figure 4a, 4b, 4c). He had also multiple axillary lymphadenopathies (LAP) and pelvic lytic lesions. There was a 6x4,5x4 cm mass expanding to the surrounding muscle with cortical destruction on the glenoid and spinous components of his right scapula on magnetic

resonance imaging (figure 5a, 5b, 5c). The biopsy of the scapular mass revealed LCH with positive CD1a staining (figure 6a, 6b). He had partial response with 2 cycles of vinblastine and steroid & still goes on chemotherapy .

Discussion

Langerhans cell histiocytosis is a rare disorder which might have atypical presentations & outcomes according to the involved sites (1-3). Histopathological evaluation needs IHC stains for histiocyte markers, like CD1a and S-100 (5,6). Both of our patients had positive staining on histopathology with atypical presentations.

The patients are classified as high or low risk according to visseral or nonvisseral involvement (13). Disseminated disease, organ dysfunction and younger age at presentation are generally poor prognostic factors while liver dysfunction was defined as the worst prognostic factor (13,14). Our first patient did well with slowly disseminating skin involvement for years and mild hypothyroidism with polydipsia due to CNS involvement for a year. However, she had worsened with liver involvement. Liver metastasis is a poor prognostic factor in LCH as mentioned above. It might mimic primary sclerosing cholangitis or nonsuppurative destructive cholangitis with cystic lesions as in our first patient. She had transaminase elevation and hyperbilirubinemia with heterogeneity & cystic lesions on liver imaging. However, she had mild regression in the liver despite prominent regression in the skin lesions after chemotherapy.

Thyroid involvement might also occur in LCH. Though skin lesions in LCH are common, scalp involvement without skull metastasis and dystrophic nail changes are

remarkable. The first patient had smoldering skin lesions, but her scalp lesions with nail dystrophy seem to differ from other common skin involvements in the literature. Hypothyroidism and DI associated with CNS involvement were under control with thyroxin & vasopressine besides chemotherapy, but RT had to be given since she had additional left hemiparesis related to the involvement of the pons.

Otologic involvement rate was 15%-61% whereas mastoid was reported as an involvement site in 4% of head and neck LCH patients (9,15). He had also scapular metastasis besides pelvic lesions. He had lateralization for mastoidal, scapular & pelvic bone lesions (i.e. all of the lesions were on the right). Bone metastasis is not rare in LCH but scapula is an uncommon site for metastasis, especially in those without disseminated bone involvement. We consider that lateralization of the involved sites, almost atypical sites for LCH seem to remarkable.

Conclusion

LCH has a widespread involvement and presentation according to the involved sites. Atypical bone metastasis and CNS involvement might accompany with other LCH involvements. Skin involvement is common, however nail dystrophy is rare. Prognosis is poor in visseral involvement, especially in liver metastasis. So, the patients with atypical presentations and/or visseral metastasis like liver involvement should be followed-up more carefully.

Conflict of interest: None




Figure 1a: Multiple erythematous-brownish papules with crusts merging to form plaques on forehead, nasolabial folds and multilobulated vegetating tumours on perioral region, left nasolabial sulcus and chin


Figure 1b: Erythematous-brownish papules scattered over trunk and coalesced to form plaques on left nipple, areola and axillary region, eosion on left axillary fold

Figure 1c: Moist, red, eroded areas on vulva and inguinal folds and a whitish, erythematous, pedunculated, fleshy mass on right inguinal fold


Figure 1d: Anonychia of all finger nails with centrally atrophic erythematous plaques with brownish to hemorrhagic crusts on distal parts of fingers.




Figures 2a, 2b: Superficial dermal infiltration of atypical, eosinophilic large cells with pale cytoplasm, indented nuclei and large nucleus; atypical cell infiltration with positive CD1a (HE, x40 and IHC, x 200)




Figures 3a, 3b, 3c: Pons involvement on axial non-contrast T1- weighted, T2-weighted & contrasted T1-weighted magnetic resonance imaging, respectively



Figures 4a, 4b, 4c: Mastoideal lesion on axial T2-weighted, non-contrast T1-weighted & contrast T1-weighted magnetic resonance imaging, respectively



Figures 5a, 5b, 5c: Scapular involvement on coronal fat-saturated T2-weighted, non-contrast T1-weighted & contrast T1-weighted magnetic resonance imaging, respectively



Figures 6a, 6b: Atypical cell infiltration with eosinophils on hematoxilin-eosin & CD1a staining (HE, x40 and IHC, x40)

References

1. Kriz J, Eich HT, Bruns F, Heyd R, Schäfer U, Haverkamp U, Büntzel J, Seegenschmiedt H, Micke O. Radiotherapy in langerhans cell histiocytosis – a rare indication in a rare disease. *Radiat Oncol* 2013; 8: 233-8.
2. Ng-Cheng-Hin B, O'Hanlon-Brown C, Alifrangis C, Waxman J. Langerhans cell histiocytosis: old disease new treatment. *QJM* 2011; 104: 89-96.
3. Narula G, Bhagwat R, Arora B, Banavali S, Pai S, Nair C, Seth T, Laskar S, Muckaden M, Kurkure P, Parikh P. Clinico-biologic profile of Langerhans cell histiocytosis: a single institutional study. *Indian J Cancer* 2007;44:93-8.
4. Arico` M, Girschikofsky M, Ge'ne'reau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E, Danesino C. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. *Eur J Cancer* 2003; 16: 2341–8.
5. Lale S, Soto D, Wasserman PG. Role of fine needle aspiration in the diagnosis of the rare disease of langerhans cell histiocytosis in a child. *Case Rep Pathol* 2014; 2014: 724895. doi: 10.1155/2014/724895.
6. Lau EG, Stepenaskie S, Moran R, Quinn R, Matthew P, Smidt AC. "Blueberry muffin" rash and large right thigh mass: a unique presentation of Langerhans cell histiocytosis. *Dermatol Online J* 2013; 19: 18568
7. Uppal P, Bothra M, Seth R, Iyer V, Kabra SK. Clinical profile of Langerhans cell histiocytosis at a tertiary centre: a prospective study. *Indian j Pediatr* 2012; 79: 1463-7.
8. Al Salloom AA, Almalki ST, Almana H, Burdelski M. Diabetes insipidus and sclerosing cholangitis in a child may be a clue to the diagnosis of langerhans' cell histiocytosis: A case report. *Int J Health Sci (Qassim)* 2013; 7: 284-51.
9. Bozdemir K, Tarlak B, Cakar H, Döblan A, Kutluhan A, Dilek I, Adıyaman Süngü N. Langerhans cell histiocytosis in bilateral mastoid cavity. *Case Rep Otolaryngol* 2013; 2013: 957926. doi: 10.1155/2013/957926.
10. Patten DK, Wani Z, Tolley N. Solitary langerhans histiocytosis of the thyroid gland: a case report and literature review. *Head Neck Pathol* 2012; 6: 279-89. doi: 10.1007/s12105-011-0321-8.
11. Aydođdu K, Günay E, Fındık G, Günay S, Ađaçkiran Y, Kaya S, Karaođlanođlu N, Taştepe I. Pulmonary langerhans cell histiocytosis; characteristics of 11 cases. *Tuberk Toraks* 2013; 61: 333-41.
12. Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. *Oncologist*. 2010;15: 1227-37.
13. Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. *Pediatr Dermatol* 2008; 25: 291-5.
14. Abdallah M, Génereau T, Donadieu J, Emile JF, Chazouillères O, Gaujoux-Viala C, Cabane J. Langerhans' cell histiocytosis of the liver in adults. *Clin Res Hepatol Gastroenterol* 2011; 35: 475-481.
15. Anonsen CK, Donaldson SS. "Langerhans' cell histiocytosis of the head and neck," *Laryngoscope* 1987; 97: 537-42.